Pharmaceutical companies dominated by heparin APIs ushered in 2017 Annual Report

[China Pharmaceutical network enterprise news] with the disclosure of 2017 annual report, the revenue situation of several listed pharmaceutical companies also surfaced On February 26, Changshan Pharmaceutical Co., Ltd issued the "2017 annual performance express" that the company's total operating revenue in 2017 reached 1420170000 yuan, an increase of 26.98% over the same period last year Changshan Pharmaceutical Co., Ltd is an enterprise dedicated to the research and development, production and sales of heparin series products After years of development, it has gradually established its position in the field of heparin APIs and heparin preparations in China The main reason for the rise in Changshan pharmaceutical's performance is that the sales price of heparin API has increased significantly compared with that in 2016, driving the growth of heparin API's revenue and gross profit, while the sales volume of water injection continues to grow, driving the performance to rise It is understood that China is the largest pig raising country in the world, with the total annual pig stock and pork output in the world, and also the largest heparin API export country in the world Based on the current international market demand, heparin API export has become the main source of income for some enterprises in China In addition to Changshan pharmaceutical industry, such as hiprise, Jianyou Co., Ltd., Qianhong pharmaceutical, etc., are also major export enterprises of heparin APIs in China So, what is the performance of these enterprises in 2017? Let's have a look On February 26, hpre released the performance express report that the company's operating revenue in 2017 was 2.694 billion yuan, an increase of 19.16% year on year During the reporting period, the company realized a total operating revenue of 2694.0775 million yuan, an increase of 19.16% over the same period of last year; an operating profit of 74.8517 million yuan, a decrease of 82.82% over the same period of last year; and a total profit of 82.9079 million yuan, a decrease of 82.54% over the same period of last year The main reasons for the change in operating performance are that the increase in the price of heparin raw materials during the reporting period resulted in the decrease in gross profit margin, the increase in financial expenses, the decrease in investment income and the one-off income brought by the US tax reform program to its US subsidiaries According to the 2017 performance report released by Jianyou Co., Ltd., the company realized a sales revenue of 1 billion 113 million yuan in 2017, an increase of 91.22% over the same period last year Performance slightly exceeded expectations Among them, the volume and price of heparin raw materials of the company rose in 2017 Sales revenue reached 919 million yuan, an increase of 95.05% over the same period last year, with a gross margin of 45.65% The sales volume of heparin API is 3.59 trillion units, up 36.72% over the same period last year The average export price is 256 million yuan / trillion unit, 42.66% higher than the same period last year Qianhong pharmaceutical on February 27, Qianhong pharmaceutical released the quick report of performance, saying that the company's operating revenue from January to December 2017 was 1.07 billion yuan, an increase of 37.81% year on year During the reporting period, the company achieved a total operating revenue of 1069903245.85 yuan, a year-on-year increase of 37.81%, which was mainly due to the company's further market development and a significant increase in both domestic and foreign sales of products; the net profit attributable to shareholders of the listed company was 183916, RMB 703.73, a year-on-year decrease of 18.06%, mainly due to the increase in the depreciation cost of the company's new plant assets, the R & D cost of innovative drugs and the investment in the market development of new varieties in the report period.